VIP (etoposide, ifosfamide, and cisplatin) in patients with previously treated soft tissue sarcoma

We retrospectively reviewed outcomes of treatment with VIP (combination of etoposide, ifosfamide, and cisplatin) in patients with previously treated soft tissue sarcoma (STS). We analyzed the medical records of patients with advanced or relapsed STS who had undergone VIP treatment as second-line or...

Descripción completa

Detalles Bibliográficos
Autores principales: Moon, Ji Young, Baek, Seung-Woo, Ryu, Hyewon, Choi, Yoon-Seok, Song, Ik-Chan, Yun, Hwan-Jung, Jo, Deog-Yeon, Kim, Samyong, Lee, Hyo Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2017
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5287961/
https://www.ncbi.nlm.nih.gov/pubmed/28121937
http://dx.doi.org/10.1097/MD.0000000000005942

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5287961/
https://www.ncbi.nlm.nih.gov/pubmed/28121937
http://dx.doi.org/10.1097/MD.0000000000005942

Ejemplares similares